Cargando…
Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
BCR-ABL oncoprotein drives the initiation, promotion, and progression of chronic myelogenous leukemia (CML). Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. A novel promising therapeutic strateg...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769755/ https://www.ncbi.nlm.nih.gov/pubmed/31527518 http://dx.doi.org/10.3390/antiox8090402 |
_version_ | 1783455311880781824 |
---|---|
author | Lu, Xuxiu Geng, Jiajia Zhang, Jinman Miao, Jinlai Liu, Ming |
author_facet | Lu, Xuxiu Geng, Jiajia Zhang, Jinman Miao, Jinlai Liu, Ming |
author_sort | Lu, Xuxiu |
collection | PubMed |
description | BCR-ABL oncoprotein drives the initiation, promotion, and progression of chronic myelogenous leukemia (CML). Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. A novel promising therapeutic strategy for CML therapy is to degrade BCR-ABL using small molecules. Antioxidant xanthohumol (XN) is a hop-derived prenylated flavonoid with multiple bioactivities. In this study, we showed XN could inhibit the proliferation, induce S phase cell cycle arrest, and stimulate apoptosis in K562 cells. XN degraded BCR-ABL in a concentration- and time-dependent manner, and the involved degradation pathway was caspase activation, while not autophagy induction or ubiquitin proteasome system (UPS) activation. Moreover, we revealed for the first time that XN could inhibit the UPS and autophagy in K562 cells, and the inhibitory effect of XN on autophagy could attenuate imatinib-induced autophagy and enhance the therapeutic efficiency of imatinib in K562 cells. Our present findings identified XN act as a degrader of BCR-ABL in K562 cells, and XN had potential to be developed as an alternate agent for CML therapy. |
format | Online Article Text |
id | pubmed-6769755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67697552019-10-30 Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells Lu, Xuxiu Geng, Jiajia Zhang, Jinman Miao, Jinlai Liu, Ming Antioxidants (Basel) Article BCR-ABL oncoprotein drives the initiation, promotion, and progression of chronic myelogenous leukemia (CML). Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. A novel promising therapeutic strategy for CML therapy is to degrade BCR-ABL using small molecules. Antioxidant xanthohumol (XN) is a hop-derived prenylated flavonoid with multiple bioactivities. In this study, we showed XN could inhibit the proliferation, induce S phase cell cycle arrest, and stimulate apoptosis in K562 cells. XN degraded BCR-ABL in a concentration- and time-dependent manner, and the involved degradation pathway was caspase activation, while not autophagy induction or ubiquitin proteasome system (UPS) activation. Moreover, we revealed for the first time that XN could inhibit the UPS and autophagy in K562 cells, and the inhibitory effect of XN on autophagy could attenuate imatinib-induced autophagy and enhance the therapeutic efficiency of imatinib in K562 cells. Our present findings identified XN act as a degrader of BCR-ABL in K562 cells, and XN had potential to be developed as an alternate agent for CML therapy. MDPI 2019-09-16 /pmc/articles/PMC6769755/ /pubmed/31527518 http://dx.doi.org/10.3390/antiox8090402 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lu, Xuxiu Geng, Jiajia Zhang, Jinman Miao, Jinlai Liu, Ming Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells |
title | Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells |
title_full | Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells |
title_fullStr | Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells |
title_full_unstemmed | Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells |
title_short | Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells |
title_sort | xanthohumol, a prenylated flavonoid from hops, induces caspase-dependent degradation of oncoprotein bcr-abl in k562 cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769755/ https://www.ncbi.nlm.nih.gov/pubmed/31527518 http://dx.doi.org/10.3390/antiox8090402 |
work_keys_str_mv | AT luxuxiu xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells AT gengjiajia xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells AT zhangjinman xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells AT miaojinlai xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells AT liuming xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells |